ArticleClinical cancer research : an official journal of the American Association for Cancer Research2023

Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas.

Arielle Elkrief et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.